MOTS-C dosage chart

Reconstitution steps

1. 1Draw 3.0 mL bacteriostatic water with a sterile syringe.
2. 2Inject slowly down the vial wall; avoid foaming.
3. 3Gently swirl/roll until dissolved (do not shake vigorously).
4. 4Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 2–4 weeks.

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes for each injection; dispose in a sharps container.
• Rotate injection sites systematically (abdomen, thighs, upper arms) to reduce local irritation and lipohypertrophy risk.
• Inject slowly; wait a few seconds before withdrawing the needle to ensure complete delivery.
• Document daily dose, time, and site rotation to maintain consistency and monitor response.
• If doses fall below 30 units (0.30 mL), consider using 50‑unit or 30‑unit insulin syringes for improved readability.
• For 2.0 mg doses exceeding single‑syringe capacity (>100 units), split into two separate injections or use 2.0 mL reconstitution.

How This Works

MOTS-C is a mitochondrial‑derived peptide that activates AMPK‑driven metabolic pathways to enhance glucose uptake, increase fat oxidation, and reduce lipid accumulation in muscle and adipose tissue. Preclinical studies demonstrate that daily MOTS-C administration (5 mg/kg i.p. in mice) prevents diet‑induced obesity and insulin resistance, while short 7‑day courses restore insulin sensitivity in aged mice to youthful levels. Unlike metformin (which acts primarily in the liver), MOTS-C directly targets skeletal muscle and fat tissues. The peptide also translocates to the nucleus under metabolic stress to regulate nuclear gene expression. Endogenous MOTS-C levels rise sharply with exercise (~12‑fold increase in muscle) and decline with age, suggesting therapeutic potential for age‑related metabolic decline. No formal human clinical trials have been completed to date; current human use is investigational and based on preclinical findings.

Potential Benefits & Side Effects

Observations from preclinical and emerging investigational use.

• Enhanced insulin sensitivity and glucose metabolism in muscle and fat tissue
• Increased fat oxidation and reduced diet‑induced obesity in animal models
• Improved exercise capacity and muscle homeostasis during aging
• Modest lifespan extension in rodents with intermittent dosing (15 mg/kg 3×/week)
• No stimulation of IGF‑1 or adverse effects on glucose tolerance (contrast with growth hormone)
• Well‑tolerated in animal studies with no severe adverse effects at typical doses
• Mild injection‑site reactions (temporary redness, inflammation, or bruising) reported anecdotally
• No severe adverse effects or organ toxicity observed in preclinical studies at standard doses
• Long‑term human safety data not yet available; chronic continuous use beyond 8 weeks remains uncharacterized
• Theoretical risk of downregulation with prolonged daily use; cycling approach (4–8 weeks on, equal time off) recommended

Lifestyle Factors

Complementary strategies for optimal metabolic outcomes.

• Pair with a balanced, protein‑forward diet tailored to energy needs; MOTS-C enhances nutrient partitioning and fat utilization.
• Combine resistance training and aerobic activity to reinforce AMPK activation and metabolic adaptations.
• Prioritize 7–9 hours of quality sleep; MOTS-C may support mitochondrial function, but recovery remains essential.
• Manage stress through mindfulness or relaxation practices; chronic stress can impair metabolic benefits.
• Maintain hydration and consider timing injections around fasted periods (e.g., morning before breakfast) to mimic exercise‑induced patterns.

Injection Technique

General subcutaneous guidance from clinical best‑practice resources.

• Clean the vial stopper and injection site with alcohol swab; allow to air‑dry.
• Pinch a skinfold (1–2 inches) at the chosen site; insert the needle at 45–90° into subcutaneous tissue.
• Do not aspirate for subcutaneous injections; inject slowly and steadily over 2–5 seconds.
• Withdraw needle at same angle; apply gentle pressure with clean cotton ball or alcohol pad (do not rub).
• Rotate sites systematically (abdomen at least 2 inches from navel, outer thighs, upper arms) to avoid lipohypertrophy or scar tissue.
• Allow refrigerated solution to reach room temperature for 5–10 minutes before injection to reduce sting.
• Dispose of used syringe immediately into puncture‑proof sharps container; do not recap needle.

important-note

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. MOTS-C is an experimental research peptide that is not approved by the FDA or other regulatory agencies for human use. It is supplied strictly for laboratory research purposes and is not for human or veterinary consumption. Any discussion of human dosing is hypothetical and for informational purposes only. Individuals should not self‑administer MOTS-C outside of properly supervised clinical research. If considering off‑label use, consult a licensed healthcare professional and comply with all applicable regulations. Neither the authors nor the supplier assume liability for off‑label use or mishandling of MOTS-C.

MOTS-C dosage FAQs